Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …

S Grunberg, D Chua, A Maru, J Dinis… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
被引用次数：267 相关文章

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …

S Grunberg, D Chua, A Maru… - Journal of Clinical …, 2011 - portal.findresearcher.sdu.dk
Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and
dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting …

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …

S Grunberg, D Chua, A Maru, J Dinis… - Journal of Clinical …, 2011 - europepmc.org
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
[PDF] academia.edu

[PDF][PDF] Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind …

S Grunberg, D Chua, A Maru, J Dinis, S DeVandry… - Clinical …, 2010 - academia.edu
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …

[引用][C] Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind …

S GRUNBERG, D CHUA, F ROILA… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and
Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE …

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …

S Grunberg, D Chua, A Maru, J Dinis… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study …

S Grunberg, D Chua, A Maru, J Dinis… - Journal of Clinical …, 2011 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Addition of aprepitant, a neurokinin-
1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves …

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study …

S Grunberg, D Chua, A Maru, J Dinis… - JOURNAL OF …, 2011 - research.unipg.it
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …

[引用][C] Single-dose fos aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …

S GRUNBERG - J Clin Oncol, 2011 - cir.nii.ac.jp
Single-dose fos aprepitant for the prevention of chemotherapy-induced nausea and vomiting
associated with cisplatin therapy : randomized, double-blind study protocol-EASE | CiNii …